News

Sinovac, China-based developer and provider of vaccines, has declared that it has completed the construction of the H1N1 virus seed bank necessary to produce a virus antigen. Sinovac

Eli Lilly has announced that it will be initiating drug discovery in new and unmet diseases, which includes Alzheimer’s disease, Cancer, Diabetes and Osteoporosis. The company’s goal is

GlaxoSmithKline has signed an agreement with Dr. Reddy’s to develop and market selected products across an extensive number of emerging markets, excluding India. Under the terms of the

Canada-based AEterna has reported that patient follow-up in the safety study of its phase-III program in benign prostatic hyperplasia (BPH) with its endocrinology compound, cetrorelix pamoate, is scheduled

Boehringer Ingelheim and Vitae have announced that they have entered into a worldwide collaboration to research and develop beta-secretase (BACE) inhibitors, for the treatment of Alzheimer’s disease. Under

Synta, a biopharmaceutical company and GlaxoSmithKline have decided to end the collaborative agreement for the clinical development and commercialization of elesclomol, effective no later than September 10, 2009.

Headquartered in California, Jazz Pharmaceuticals has declared that its pain drug JZP-6 has shown clinically significant improvement in pain and core symptoms, associated with fibromyalgia. The result was

California-based pharmaceutical company, Transdel has announced that it anticipate reporting top-line results from its current phase-III study of Ketotransdel during the third quarter of 2009. The phase-III study

New York-based NeoStem has announced that it has signed an exclusive 10 year agreement with Enhance BioMedical, a Shanghai-based company, to develop a Stem Cell Collection and Treatment